Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study

dc.contributor.authors	Uncu D, Bayoglu IV, Arslan UY, Kucukoner M, Artac M, Koca D, Oguz A, Demirci U, Arpaci E, Dogan M, Kucukzeybek Y, Turker I, Isikdogan A, Guler T, Zengin N
dc.date.accessioned	2020-02-27T08:42:49Z
dc.date.available	2020-02-27T08:42:49Z
dc.date.issued	2015
dc.identifier.citation	Uncu D, Bayoglu IV, Arslan UY, Kucukoner M, Artac M, Koca D, Oguz A, Demirci U, Arpaci E, Dogan M, Kucukzeybek Y, Turker I, Isikdogan A, Guler T, Zengin N (2015). Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study. Asian Pac J Cancer Prev. , 16(9):, 31-4127
dc.identifier.uri	https://hdl.handle.net/20.500.12619/66771
dc.title	Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study
dc.identifier.volume	16(9):
dc.identifier.startpage	4127
dc.identifier.endpage	31
dc.contributor.department	Sakarya Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri Bölümü
dc.contributor.saüauthor	Bayoğlu, İbrahim Vedat
dc.relation.journal	Asian Pac J Cancer Prev.
dc.contributor.author	Bayoğlu, İbrahim Vedat